methyl (1,3,7-trimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)acetate 、 、 盐酸 在
盐酸 、 silica gel 作用下,
反应 2.0h,
以to obtain 94 mg of the product as a white solid的产率得到(1,3,7-trimethyl-2,4-dioxo-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)acetic acid
参考文献:
名称:
FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS
FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS
申请人:Chaudhari Sachin Sundarlal
公开号:US20120041004A1
公开(公告)日:2012-02-16
The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS
申请人:Glenmark Pharmaceuticals, S.A.
公开号:US20140128603A1
公开(公告)日:2014-05-08
The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators
申请人:Glenmark Pharmaceuticals S.A.
公开号:EP2708538A1
公开(公告)日:2014-03-19
The present invention relates to a process for preparing a compound of formula (Id-1)
or a pharmaceutically acceptable salt thereof, which comprises
reacting a compound of formula (35) with amine compound of formula (18)
wherein,
R1 and R2, which may be same or different, are independently selected from hydrogen and substituted or unsubstituted alkyl;
U is substituted or unsubstituted heterocycles selected from thiazole and isoxazole; and
V is substituted or unsubstituted aryl.
本发明涉及一种制备式(Id-1)化合物的工艺
或其药学上可接受的盐的工艺,该工艺包括
使式(35)化合物与式(18)胺化合物反应
其中
R1 和 R2(可以相同或不同)独立地选自氢和取代或未取代的烷基;
U 是取代或未取代的杂环,选自噻唑和异噁唑;以及
V 是取代或未取代的芳基。